EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

The association between weight loss medications and cardiovascular complications

Onur Baser iD, Gabriela Samayoa, Katarzyna Rodchenko, Lauren Isenman, Erdem Baser, Nehir Yapar

Obesity · 2024

DOI: 10.1002/oby.24037 ↗

At a glance

Journal article in Obesity, 2024. Written by Onur Baser and 5 co-authors. Institution: Department of Economics, Bogazici University, Istanbul, Turkey. Major MEDLINE topics: Cardiovascular Diseases, Obesity, Anti-Obesity Agents. Cited 26 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

Obesity and its cardiovascular complications are major causes of morbidity and mortality. Little is known in real‐world settings about the effect of newly approved antiobesity medications (AOMs) on cardiovascular complications among patients with obesity.

Methods

This retrospective cohort study examined the association between newly approved AOM use and cardiovascular events among Medicare patients with obesity using data from 2020 to 2022. Patient age, gender, comorbidity scores, socioeconomic status, and baseline cardiovascular comorbidities were compared descriptively. Subgroup analysis compared variables by medication type. Relative risk and absolute risk of cardiovascular disease (CVD) events were estimated using Cox and Aalen regression models.

Results

The analysis included 5926 patients treated with semaglutide and tirzepatide, including Ozempic (5404 patients), Wegovy (375 patients), or Mounjaro (147 patients). Hypertension, type 2 diabetes, and hyperlipidemia were the most common comorbidities. For patients with AOMs, less incidence of heart failure (4.89% vs. 6.13%, p < 0.0001), atrial fibrillation (3.83% vs. 5.17%, p < 0.0001), arrhythmia (3.59% vs. 4.14%, p < 0.0153), and peripheral vascular disease (3.44% vs. 2.94%, p < 0.0395) was found versus patients without AOMs. Patients receiving AOMs showed an 8% risk reduction in any CVD. Protective effect on CVD was apparent over the first 375 days.

Conclusions

Results suggest that utilization of AOMs effectively alleviates the high prevalence of CVD.

Subjects

MeSH terms (MEDLINE)

Cardiovascular DiseasesObesityAnti-Obesity AgentsHumansMaleFemaleRetrospective StudiesAgedUnited StatesComorbidityDiabetes Mellitus, Type 2Aged, 80 and overMedicareMiddle AgedWeight LossIncidenceHypertensionRisk FactorsHyperlipidemiasGlucagon-Like PeptidesSemaglutide

Substances

Anti-Obesity AgentsGlucagon-Like PeptidesSemaglutide

Authors and institutions

  • Department of Economics, Bogazici University, Istanbul, Turkey.
  • Graduate School of Public Health, City University of New York, New York, New York, USA.
  • Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Columbia Data Analytics, New York, New York, USA.
  • Columbia Data Analytics, Ann Arbor, Michigan, USA.

ORCID profiles: Onur Baser

Cite

APA

Baser, O., Samayoa, G., Rodchenko, K., Isenman, L., Baser, E., & Yapar, N. (2024). The association between weight loss medications and cardiovascular complications. Obesity. https://doi.org/10.1002/oby.24037

Vancouver

Baser O, Samayoa G, Rodchenko K, Isenman L, Baser E, Yapar N. The association between weight loss medications and cardiovascular complications. Obesity. 2024. doi:10.1002/oby.24037

BibTeX
@article{Baser2024,
  author = {Baser, Onur and Samayoa, Gabriela and Rodchenko, Katarzyna and Isenman, Lauren and Baser, Erdem and Yapar, Nehir},
  title = {The association between weight loss medications and cardiovascular complications},
  journal = {Obesity},
  year = {2024},
  doi = {10.1002/oby.24037}
}
Start for free →